Piramal Pharma to Invest USD 90 Million in Expanding US Facilities

Mumbai-based Piramal Pharma Limited has made a USD 90 million investment to build out two of its facilities in the US. The announcement comes on the backdrop of the 2025 Select USA Investment Summit and reflects the company's intent to encourage the trend of on shoring pharma manufacturing in the US.

The proposed investments, which will be financed by a mix of bank borrowings and internal accruals, will be in the form of brownfield expansions—a strategy Piramal Pharma finds to be the most cost-effective, low-risk, and quickest way to ramp up operations and cater to soaring US market demand.

On the sterile compounding, liquid fill, and injectable drug product lyophilization focus in its Lexington, Kentucky plant, Piramal is adding 24,000 square feet of manufacturing capacity plus a new laboratory. The addition will greatly augment the site's commercial-scale capability to facilitate more streamlined production scale-up for customers. The new additions will be a new fill line, two high-capacity lyophilizers, a high-end capping machine, and an external vial washer. The completion is anticipated in late 2027.

At the same time, the firm's Riverview, Michigan facility—long recognized for more than half a century as a center of API and HPAPI development and manufacturing—is to have its capabilities further expanded with the addition of a new commercial-scale suite for payload-linker development. These potent compounds are a key component in the production of antibody-drug conjugates (ADCs) and other bioconjugate medicines. The new suite will come online by the end of 2025.

"Since its inception, Piramal Pharma Ltd has invested $570 million in its US drug development and manufacturing capabilities," said Peter DeYoung, Chief Executive Officer, Global Pharma. "The US is our largest market, where we currently employ approximately 750 people. Expanding the capacities and offerings in these two plants in the US, along with the prior major investments made in our Sellersville PA drug product facility, and our inhalation anesthesia drug substance and drug product facility in Bethlehem PA, will support our customers who value our offerings in an onshore setting."